A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- iCell Gene Therapeutics
- Study ID
- NCT07328581
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Lupus Nephritis (LN)
- Systemic Lupus Erythematosus (SLE)
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion — BIOLOGICALAnti-BCMA, Anti-CD19 Compound CAR-T Cells
Study Details
This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.
Key Dates
- First listed
- Jan 9, 2026
- Start date
- Sep 30, 2026
- Status verified
- Sep 2026
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Single armBiologic drug infusion
Primary Outcome Measure
Number of Adverse Events after ICG318 infusion [ Time Frame: Starting day 0 and up to 1 year after ICG318 infusion. ]
Central Contacts
- Adam Chowdhury, MD, MBA2404238999
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Chicago | Chicago | Illinois | 60637 | |
| New York Medical College | Hawthorne | New York | 10532 | |
| NorthWell | New Hyde Park | New York | 11040 | |
| Fox Chase Cancer Center- Temple BMT | Philadelphia | Pennsylvania | 19111 |
Find similar trials in Chicago, IL
Related Studies
- An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusPHASE3 · Enrolling By Invitation · Biogen · Phoenix, Arizona
- Lupus Landmark Study: A Prospective Registry and BiorepositoryRecruiting · Lupus Research Alliance · Birmingham, Alabama
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune DiseasePHASE1 · Recruiting · Fate Therapeutics · Beverly Hills, California
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune DiseasePHASE1 · Enrolling By Invitation · Adicet Therapeutics · Redwood City, California